Shelf life (days): 1460.0
Formulation: A solid
Formal Name: (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid, 1,14-di(methyl-d3) ester
Purity: ≥99% deuterated forms (d1-d6)
Formula Markup: C38H46D6N6O7
Formula Weight: 710.89208
CAS Number: 1092540-50-5
Notes: Atazanavir-d6 is intended for use as an internal standard for the quantification of atazanavir (Item No. 11733) by GC- or LC-MS. Atazanavir is an azapeptide inhibitor of HIV-1 protease (Ki = 2.66 nM).{24185} It has antiviral activity against a variety of HIV-1 strains in several cell types with EC50 values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Item No. 15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.{24184} Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.
English
Deutsch
